Resveratrol

botanical

provenance:botanical

first introduced:2003

regulatory status:supplement

context:Resveratrol is a stilbene polyphenol found in the skin of grapes and in red wine, isolated by Japanese chemists in 1939 and long studied for a possible role in the 'French Paradox' (low cardiovascular disease despite a high-fat diet). It entered longevity science in 2003, when David Sinclair's laboratory reported it as the most potent of several small-molecule activators of the yeast enzyme Sir2 and its human homolog SIRT1, extending yeast replicative lifespan by roughly 70% in a Sir2-dependent manner (Howitz et al., Nature, 2003).

MECHANISM CLAIMED

Activates SIRT1, an NAD+-dependent deacetylase proposed to mediate the lifespan-extending effects of calorie restriction, thereby mimicking calorie restriction's health and longevity benefits without requiring reduced food intake.

MECHANISM ACTUAL

A 2010 Pfizer study (Pacholec et al., Journal of Biological Chemistry) found that resveratrol and several synthetic 'sirtuin-activating compounds' developed by Sirtris do not directly activate SIRT1 against native, unlabeled substrates; the original activation signal depended on a fluorescent reporter group attached to the test peptide, an assay artifact. Resveratrol also has poor oral bioavailability in humans (it is rapidly metabolized), and human trials have not shown convincing evidence that it slows aging or produces the cardiovascular/anti-inflammatory benefits once predicted (The Conversation, 20 May 2026). A Sirtris-sponsored Phase 2 trial of a micronized resveratrol formulation (SRT501) in multiple myeloma patients was terminated after 5 of 24 patients developed renal failure (Popat et al., British Journal of Haematology, 2013).

INTERVENTIONS USING IT

Sirtuin-activating compounds (resveratrol, then NMN)

EXTERNAL REFERENCES

Wikipedia

NOTES

Resveratrol is the compound that launched this case: the 2003 finding that it activated SIRT1 and extended yeast lifespan led directly to the founding of Sirtris Pharmaceuticals, its $720 million acquisition by GlaxoSmithKline, and, after the underlying assay was shown to be an artifact and a clinical trial was halted for a serious adverse event, GlaxoSmithKline’s 2013 shutdown of the Sirtris research program. It remains sold today as an unregulated dietary supplement, marketed on the residual popular association with longevity that the original 2003 finding created, though no human trial has demonstrated it slows aging.